{"id":"lenalidomide-dexamethasone-dli","safety":{"commonSideEffects":[{"rate":"40%","effect":"Neutropenia"},{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Anemia"},{"rate":"50%","effect":"Fatigue"},{"rate":"30%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"10%","effect":"Vomiting"},{"rate":"20%","effect":"Headache"},{"rate":"10%","effect":"Dizziness"},{"rate":"10%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lenalidomide works by inhibiting the proteasome, which leads to the accumulation of ubiquitinated proteins and the activation of immune cells. Dexamethasone has anti-inflammatory and immunosuppressive effects, which can help to reduce the risk of graft-versus-host disease. DLI is used to treat relapsed or refractory hematologic malignancies after allogeneic hematopoietic stem cell transplantation.","oneSentence":"Lenalidomide is an immunomodulatory drug that targets the ubiquitin-proteasome pathway, and Dexamethasone is a corticosteroid that modulates the immune response. DLI (Donor Lymphocyte Infusion) is a form of immunotherapy that involves infusing donor lymphocytes to treat hematologic malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:41:59.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"},{"name":"Myelodysplastic syndromes"}]},"trialDetails":[{"nctId":"NCT03413800","phase":"PHASE2","title":"Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-02-12","conditions":"Relapsed Hematologic Malignancy, Multiple Myeloma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lenalidomide-Dexamethasone-DLI","genericName":"Lenalidomide-Dexamethasone-DLI","companyName":"Ciusss de L'Est de l'Île de Montréal","companyId":"ciusss-de-l-est-de-l-le-de-montr-al","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide is an immunomodulatory drug that targets the ubiquitin-proteasome pathway, and Dexamethasone is a corticosteroid that modulates the immune response. DLI (Donor Lymphocyte Infusion) is a form of immunotherapy that involves infusing donor lymphocytes to treat hematologic malignancies. Used for Multiple myeloma, Mantle cell lymphoma, Myelodysplastic syndromes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}